A prospective study to evaluate clinical outcomes of targeted axillary dissection after neoadjuvant chemotherapy in Node-positive breast cancer patients

A prospective study to evaluate clinical outcomes of targeted axillary dissection after neoadjuvant chemotherapy in Node-positive breast cancer patients - Axillary evaluation with targeted axillary dissection

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000057643

Enrollment

100

Registered

2025-04-17

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

After placing a marker in the axillary lymph nodes with metastasis, neoadjuvant chemotherapy is performed. The lymph nodes with the marker and the sentinel lymph nodes are removed at the time of surge

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with breast cancer with 1-3 metastases in the axillary lymph nodes and scheduled for neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant, may be pregnant, within 28 days of giving birth, or breastfeeding. 2. Those who suffer from a psychiatric disorder or symptoms that interfere with their daily life and are deemed to have difficulty participating in the study. 3. Those who the principal investigator judges to be inappropriate as study subjects.

Design outcomes

Primary

Measure	Time frame
Safety, axillary recurrence rate, and complication rate	—

Countries

Japan

Contacts

Public ContactKiyomi Kimura

Juntendo University Nerima Hospital Department of Breast Surgery

k.kimura.bq@juntendo.ac.jp03-5923-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026